Hepatitis C Medicine Trial Shows 100% Cure Rate
Category: WELLNESS
Mark Schoenebaum, a biotech analyst with ISI Group, said in a research note that he expects Gilead shares to rise on Monday
By Reuters, Reuters, 2012-11-10